NASDAQ: MCRB Receives A “Buy” Rating From Stock Market Brokerages


Seres Therapeutics Inc (NASDAQ: MCRB) earned an average consensus of “buy” rating from ten stock market analysts. Eight brokerages issued a rating of “buy.” Meanwhile, one issues a rating of “sell” and another issued a rating of “hold.” The average target price for 12 months stands at $34.75. 

Top Stock Market Brokerages React To NASDAQ: MCRB Buy Rating

Several brokerages reacted to Seres Therapeutics’ average “buy” rating. HC Wainwright increased its objective price to $41.00 from $8.00. They also issued a rating of “buy” on 11th August, during the Tuesday reports. ValuEngine also shifted its Seres Therapeutics rating of “hold” to a “buy” rating. Similarly, BidakClub updated its rating of “hold” to a rating of “buy” on 17th September during the Thursday report. 

On the other hand, Chardan Capital downgrades it’s NASDAQ: MCRB “buy” to a rating of “neutral.” Furthermore, on 18th September, Chardan Capital decreased its Seres Therapeutics stock price target to $27.5” from $32.50. Last but not the least, Oppenheimer issued a rating of “buy” and announced its price target of $29.00 on 13th September during the Sunday report. 

Here’s How Stock Market Investors Shifted Gears With Seres Therapeutics Inc

For the first quarter, the Royal Bank of Canada increased its NASDAQ: MCRB position by 227.2 percent. Currently, the Royal Bank of Canada owns at least 10,445 shares in company stock. 

Advisor Group Holdings Inc purchased a position in the company recently. The first quarter estimation came to $38,000. For the first quarter, BNP Paribas Arbitrage SA increased its company shareholdings by 162.4 percent. Currently, BNP Paribas Arbitrage owns at least 11,351 NASDAQ: MCRB shares. It’s estimated to be $41,000. 

FDx Advisors Inc purchased Series Therapeutics shares estimated at $49,000 recently. Last but not the least, Bank of America Corp DE increased its company shares position by 33.7 percent. Currently, the Bank of American Corp DE owns at least 11,203 NASDAQ: MCRB shares. It’s estimated to be $54,000. 

It should be noted that at least 94.42 percent of Seres Therapeutics Inc stock is under several hedge funds and stock market investors. 

On Friday, Seres Therapeutics Inc shared started with $31.62. The company’s average movie price of 50 days is $25.84. Its average moving price for 200 days is $10.61. The company’s one year high stands at $33.00, and its one year low stands at $2.52. Seres Therapeutics’ market capitalization stands at $2.41 billion. 

NASDAQ: MCRB last released its earnings on 28th July, during the Tuesday report. It’s earning spee share stood at $0.28. While the stock market analysts had expected that company’s revenue to reach $9.67 million, its revenue was reported to be $6.05 million.